Dr Mathew Maurer (Columbia University, New York, US) provides an overview of the CARDIO-TTRansform trial design, the significance of baseline data, and what this may mean for future practice.
For a deeper dive and discussion, you can watch more videos in Updates on Cardiomyopathies.
Watch this series of short videos providing an focused review of new cardiomyopathy data presented at the Heart Failure Association (HFA) Congress 2026.
In these concise sessions, a leading global expert offers rapid, high-impact analysis of late-breaking clinical trials. Each video highlights trial design, primary endpoints, and the immediate relevance of findings to current treatment pathways.
All videos have been recorded on site at HFA 2026 in Barcelona, Spain.
Target Audience
- Cardiologists
- Heart failure Specialists
More from this programme
Part 1
Data Highlights: CARDIO-TTRansform Design and Baseline Characteristics
Dr Mathew Maurer (Columbia University, New York, US) provides an overview of the CARDIO-TTRansform trial design, the significance of baseline data, and what this may mean for future practice.
For a deeper dive and discussion, you can watch more videos in Updates on Cardiomyopathies.
Part 2
Perhexiline in HCM: Key Insights from RESOLVE-HCM
Dr Joseph Selvanayagam (Flinders University and Flinders Medical Centre, Adelaide, AU) shares insights from the RESOLVE-HCM study, focusing on unmet needs in symptomatic patients and the rationale for metabolic therapy. He summarises the trial design and highlights results showing left ventricular hypertrophy (LVH) regression along with improvements in symptoms and function.
Faculty Biographies
Mathew S Maurer
Arnold and Arlene Goldstein Professor of Cardiology
Dr Mathew S Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus. He is the Director of the Cardiac Amyloidosis Program.
He has published over 300 articles including peer reviewed manuscripts, reviews and book chapters. He was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organisation dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for…
Comments